Joseph Fortunak - Immune Therapeutics VP
VP
Dr. Joseph M. Fortunak is Vice President of Global Research and Development and Chemical Development of the Company. He graduated from the University of WisconsinMadison with a PhD in Organic Chemistry. After spending time holding a postdoctoral position at Cambridge University, he spent over 20 years in the pharmaceutical industry, most recently as Director and Head of Global Process Research and Development at Abbott Laboratories, from 2000 to 2004. Before taking the position at Abbott Laboratories, from 1983 to 1993, Dr. Fortunak worked as Associate Senior Research Investigator, Senior Research Investigator, and Assistant Director for Smith Kline Beechman, and from 1993 to 2000 was the Associate Director, Director, Senior Director, and Executive Director of DuPont Pharmaceutical Company. In 2004, Dr. Fortunak assumed the position of Associate Professor of Chemistry and Pharmaceutical Sciences at Howard University in Washington, D.C., with a goal of developing an international program for cGMP practices worldwide since 2013.
| Age | 68 |
| Tenure | 12 years |
| Professional Marks | CPA |
| Phone | 888 613 8802 |
| Web | https://www.immunetherapeutics.com |
Immune Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.4526) % which means that it has lost $0.4526 on every $100 spent on assets. This is way below average. Immune Therapeutics' management efficiency ratios could be used to measure how well Immune Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Immune Therapeutics currently holds 1.08 M in liabilities with Debt to Equity (D/E) ratio of 1.97, which is about average as compared to similar companies. Immune Therapeutics has a current ratio of 0.04, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Immune Therapeutics until it has trouble settling it off, either with new capital or with free cash flow. So, Immune Therapeutics' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Immune Therapeutics sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Immune to invest in growth at high rates of return. When we think about Immune Therapeutics' use of debt, we should always consider it together with cash and equity.
Immune Therapeutics, Inc. does not have significant operations. Immune Therapeutics, Inc. is headquartered in Orlando, Florida. Immune Therapeutics operates under Biotechnology classification in the United States and is traded on OTC Exchange. Immune Therapeutics [IMUN] is a Pink Sheet which is traded through a dealer network over-the-counter (OTC). Management Performance
| Return On Asset | -0.45 |
Immune Therapeutics Leadership Team
Elected by the shareholders, the Immune Therapeutics' board of directors comprises two types of representatives: Immune Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Immune. The board's role is to monitor Immune Therapeutics' management team and ensure that shareholders' interests are well served. Immune Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Immune Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Glen MBA, Chief Officer | ||
| Joseph Fortunak, VP of Global RandD and Chemical Devel. and Member of Advisory Board | ||
| Peter Aronstam, CFO | ||
| FMedSci FRACP, Chief RD | ||
| Kelly Wilson, Interim Pres |
Immune Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Immune Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.45 | |||
| Current Valuation | 83.25 M | |||
| Shares Outstanding | 82.76 M | |||
| Shares Owned By Insiders | 29.51 % | |||
| Price To Earning | 333.33 X | |||
| Price To Sales | 161.50 X | |||
| Gross Profit | 65.83 K | |||
| EBITDA | 3.8 M | |||
| Net Income | 3.59 M | |||
| Cash And Equivalents | 271.53 K |
Pair Trading with Immune Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Immune Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Immune Therapeutics will appreciate offsetting losses from the drop in the long position's value.The ability to find closely correlated positions to Unum could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Unum when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Unum - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Unum Group to buy it.
The correlation of Unum is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Unum moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Unum Group moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Unum can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Investing Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Other Consideration for investing in Immune Pink Sheet
If you are still planning to invest in Immune Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Immune Therapeutics' history and understand the potential risks before investing.
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| ETF Categories List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments | |
| Cryptocurrency Center Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences |